Sudeep Pharma Limited — Investor Meet, 28-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sudeep Pharma Limited hosted an earnings conference call to discuss its Q4 and FY26 financial and operational performance. Management provided an overview of strategic milestones, including a successful listing, acquisition in Europe, and progress on manufacturing expansions and a battery material project, all achieved amidst a challenging global environment. The call highlighted growth drivers, business verticals, and future outlook.

**Financial Performance:**

* **FY26 Revenue:** Grew 27.9% YoY to INR642.3 Cr.

* **FY26 EBITDA:** Increased 16.8% YoY to INR221.9 Cr. EBITDA margin stood at 34.6% (vs 37.8% in FY25).

* **FY26 PAT:** Reached INR174.3 Cr (vs INR138.7 Cr in FY25).

* **Q4 FY26 Revenue:** Up 15.7% YoY to INR182.3 Cr.

* **Q4 FY26 EBITDA:** INR62.6 Cr (vs INR58.8 Cr in Q4 FY25), with a margin of 34.3%.

* **Q4 FY26 PAT:** INR48.5 Cr (vs INR44.2 Cr in Q4 FY25).

* **Business Mix:** Exports contributed 60%, domestic 40%. Specialty ingredients were 44%, Pharma Food & Nutrition (PFN) 56% of FY26 revenue.

* **Working Capital:** Increased to 213 days, primarily due to strategic inventory build-up for continuity and customer commitments. Targeting 150-160 days.

* **Debt:** Net debt stood at INR33.6 Cr, with a net debt-to-equity of 0.04x.

**Management Commentary & Outlook:**

* FY26 was transformational with investments in capacity, global presence, and new growth platforms.

* PFN vertical grew 10% YoY, driven by calcium and iron portfolios, with new products like bisglycinate poised for higher value.

* Specialty ingredients is the fastest-growing segment (62% revenue growth), driven by infant nutrition, medical nutrition, and dietary supplements. Strong momentum in North America and Europe is expected to continue.

* The new greenfield facility will enhance capabilities in high-value molecules.

* The battery materials project at Dahej is on track, with Phase 1 capacity of 25,000 MTPA expected by April 2027. The company is a potential ex-China supplier for battery-grade iron phosphate.

* FY27 outlook is positive, with PFN expected to grow faster than FY26 and specialty ingredients maintaining momentum. Consolidated margins are expected to recover towards historical levels of 37-38% in FY27.

* Excluding battery materials, the core business can scale to INR1000-1200 Cr with existing capacity.

**Analyst Q&A Highlights:**

* PFN volume growth was over 20%, with pricing benefits expected to reflect in Q1/Q2 FY27. New facility commissioning will improve flexibility for phosphate off-takes.

* EBITDA for PFN is impacted by higher operational costs for new molecules at lower capacities and pre-commissioning employee expenses.

* Other expenses increase in Q4 FY26 was due to one-time CSR expenditure, premium LPG costs, and air freight for a key customer. These are expected to normalize.

* The company secured ~700 MT orders for battery materials and is utilizing existing pharma capacity to service them. FY27 sales of battery chemicals are expected to be around 2,500 MT.

* Specialty segment growth is supported by approvals in encapsulation technology and premix for infant nutrition.

* Total battery material capex for 100,000 MT capacity is estimated at INR600 Cr, with a revenue potential of INR1600-1800 Cr at peak utilization.

* FY27 capex will be mainly maintenance, with limited spending on completing the greenfield project.

* New molecules like bisglycinate offer significantly higher realization (up to 4x) and are a key driver for future margin expansion.

**Investor Angle:** The company demonstrates robust growth in specialty ingredients and a strategic push into battery materials. Investments in new facilities and products are expected to drive future growth and margin improvement, positioning Sudeep Pharma for sustained expansion.